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Abstract
Aim: To develop prognostic nomograms for predicting outcomes in patients with locally advanced rectal cancers who do
not receive preoperative treatment.
Materials and Methods: A total of 883 patients with stage II–III rectal cancers were retrospectively collected from a single
institution. Survival analyses were performed to assess each variable for overall survival (OS), local recurrence (LR) and
distant metastases (DM). Cox models were performed to develop a predictive model for each endpoint. The performance of
model prediction was validated by cross validation and on an independent group of patients.
Results: The 5-year LR, DM and OS rates were 22.3%, 32.7% and 63.8%, respectively. Two prognostic nomograms were
successfully developed to predict 5-year OS and DM-free survival rates, with c-index of 0.70 (95% CI = [0.66, 0.73]) and 0.68
(95% CI = [0.64, 0.72]) on the original dataset, and 0.76 (95% CI = [0.67, 0.86]) and 0.73 (95% CI = [0.63, 0.83]) on the validation
dataset, respectively. Factors in our models included age, gender, carcinoembryonic antigen value, tumor location, T stage,
N stage, metastatic lymph nodes ratio, adjuvant chemotherapy and chemoradiotherapy. Predicted by our nomogram,
substantial variability in terms of 5-year OS and DM-free survival was observed within each TNM stage category.
Conclusions: The prognostic nomograms integrated demographic and clinicopathological factors to account for tumor and
patient heterogeneity, and thereby provided a more individualized outcome prognostication. Our individualized prediction
nomograms could help patients with preoperatively under-staged rectal cancer about their postoperative treatment
strategies and follow-up protocols.
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Background
Colorectal cancer is the most commonly diagnosed gastrointes-
tinal malignancy in the world. As most of patients with rectal
cancer present with locally advanced disease at diagnosis,
neoajuvant chemoradiation is the standard recommendation to
improve patients’ outcomes including quality of life. Compared to
colon cancer, treatment is more heterogeneous in rectal cancer. In
real clinical practice, approximately 20–50% of patients with stage
II–III rectal cancer in North America receive definitive surgery
prior to adjuvant treatment [1,2], and the proportion is even
higher in Asia [3]. The reasons for not giving neoadjuvant therapy
may be multifarious. Although neoadjuvant chemoradiotherapy
(CRT) has been confirmed to improve local control for locally
advanced rectal cancer, its efficacy in preventing distant metas-
tases and improving OS remains controversial [4]. Because
preoperative CRT is associated with increased complications
compared to surgery alone, we sought to characterize patients with
locally advanced rectal cancer who were adequately treated with
surgery followed by adjuvant chemotherapy[5–7].
Currently, the TNM stage system from the American Joint
Commission on Cancer (AJCC) and the International Union
Against Cancer [8,9] is the most reliable prognostic system for all
stages of rectal cancer patients with or without preoperative
treatment [10,11]. However, TNM staging does not integrate
demographic features like age, or other pathological features like
histopathology, perineural invasion, or tumor location, into a
patient’s outcome prediction. More individualized outcome
prediction models could help physicians advise patients about
personalized treatment strategies and follow-up protocols.
Developing a nomogram for prognosis or treatment prediction
has been considered helpful in individualized medicine and
successful applications have been utilized in many malignan-
cies[12–15]. This statistically based tool provides a predicted
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probability of a specific outcome, using a combined set of proven
or potential prognostic factors. Recently, a nomogram was
developed to predict outcomes of locally advanced rectal cancers
with preoperative radiotherapy or CRT [16]. However, due to
changes in pathological features after preoperative treatment, this
nomogram only applies to patients who receive preoperative
treatment. Our study was designed to develop prognostic
nomograms for patients with locally advanced rectal cancer who
did not receive preoperative treatment.
Materials and Methods
Ethics
A retrospective study was conducted at the Fudan University
Shanghai Cancer Center. This study was approved by the Fudan
University Shanghai Cancer Center Institutional Ethics Commit-
tee. According to hospital routine, patients are asked to provide a
written informed consent after their admission that their clinical
and outcome information will be used in future scientific studies.
Patients’ records and follow-up information were anonymized and
de-identified prior to analysis. The institutional Ethics Committee
approved the exception of informed consent if informed consent
could not be obtained due to patients’ death or lost of follow-up in
our institutional database.
Patient Population
All patients with AJCC stage II–III (restaged according to 7th
Edition) [8] rectal cancers were collected from the institutional
colorectal cancer database. The statistical analyses were performed
for patients operated between 1986 and 2005 (N= 833), whose
tumors were located within 15 cm from anal verge. Patients who
met one of the following criteria were excluded: (1) received
preoperative treatment, (2) synchronous distant metastases, (3)
surgery without curative intent, and (4) complete loss of follow-up
after surgery.
An independent group of patients with stage II–III rectal cancer
(N= 84) who were operated between January 2006 and June 2007
were selected for validation (Table 1).
Follow-up
According to institutional follow-up protocol, all patients were
asked to follow-up every 3–6 months after surgery in the first 3
years, and 6–12 months thereafter in the next two years. Follow-
up information was recorded in the database. A minimum follow-
up of 60 months was required for the patients who are alive in the
validation dataset so that their 5-year survival status is known. The
primary endpoint is the overall survival (OS) time. Local
recurrence (LR) time and distant metastases (DM) time are the
secondary endpoints. The LR time was calculated from the time of
surgery to the time when cancer recurrence was determined in the
pelvis or anastomosis by physical examination, colonoscopy, or
imaging studies. The DM time was defined from the time of
surgery to the identification of distant recurrence. There were
three times of massive follow-up for all off-records patients via mail
or telephone in1996, 2002, and 2007.
Statistical Model Creation
Kaplan-Meier plots and log-rank tests were performed for
each potential predictive variable for the primary endpoint OS
and the secondary endpoints LR and DM. Cox proportional
hazards (PH) model was performed to develop the predictive
model for OS. All decisions with respect to the grouping of the
categorical variables and categorizing the continuous variables
were made before modeling. These predictive models were the
basis for the nomograms and the estimated probabilities of
interest (e.g., 5-year OS) were calculated and presented in the
nomograms.
Model Validation
Each nomogram went through two validation procedures:
internal validation using the study patients for the model
creation and external validation using the independent valida-
tion patients. For each outcome variable, the predicted
probability from the nomogram was compared with the actual
status (e.g., alive or dead 5 years from surgery) for these
uncensored observations. In addition, the Harrell’s concordance
index (c-index) was calculated for each nomogram [17]. This
index calculates the proportion of all usable patient pairs in
which the predictions and the outcomes are concordant and has
a similar interpretation to that of the AUC. All the above
validation analyses were performed for the study patient data
and the independent validation data.
All the statistical analyses were performed using R 3.0.1.
Results
Outcomes and survival analyses
Of the 833 patients with locally advanced rectal cancer in
training group, 267 patients (32%) experienced local recurrence
and/or distant metastases, and 263 patients (31.5%) died of cancer
or other reasons up to our last follow-up. Of those alive, median
follow-up time was 51 months. The 5-year LR, DM, OS
probabilities (estimated using Kaplan-Meier method) for all
patients were 22.3%, 32.7% and 63.8%, respectively.
Demographic and clinicopathologic variables that potentially
predict OS, LR and DM were collected, including age, gender,
tumor location, preoperative carcinoembryonic antigen level
(CEA), tumor differentiation, tumor histopathology, number of
metastatic lymph nodes, number of total sampled lymph nodes,
lymphovascular invasion, perineural invasion, T classification, N
classification and adjuvant treatment. For each outcome variable
(LR, DM, and OS), univariate analysis identified statistically
significant predictors in the demographic features, clinical features,
pathological features and treatment modalities. 5-year local
control, distant control and overall survival rates were provided
for every category of each predictor with p-values obtained from
the Log-rank tests (Table 1).
Nomograms
For the development of nomograms, all patients in the main
dataset were included (N= 833), and the nomograms were
validated using the external dataset (N= 84). Two nomograms
for overall survival and distant metastases were successfully
developed (Figure 1). The predictors included in the nomograms
are gender, age (,=49, 50–69, .=70), tumor location (,5 cm,
5 cm-10 cm, .10 cm), adjuvant chemotherapy (No/Yes), adju-
vant chemoradiotherapy (No/Yes), T classification (T1–T2, T3,
T4), N classification (N0, N1a, N1b, N2a, N2b), CEA (,=5, .5)
and ratio of metastatic lymph nodes. Table 2 presents the hazard
ratio (HR) with 95% CI and the pvalue for each predictor, and the
c-index for the main dataset and the external dataset respectively.
For OS prediction, the c-index was 0.76 in external validation,
with a 95% CI of 0.67 to 0.86. Similarly, for DM prediction, the c-
index was 0.73 (95% CI, 0.63–0.84). However, the nomogram for
local recurrence prediction was not developed because of the poor
c-index value in external validation (c-index, 0.6; 95% CI, 0.45–
0.75).
Nomograms for Outcomes in Rectal Cancer
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Predicted events within each AJCC stage classification
Within each AJCC stage (7th Edition), the 5-year OS rates were
82.2% (stage IIA), 70.2% (stage IIB–C), 70.1% (stage IIIA), 57.0%
(stage IIIB) and 44.8% (stage IIIC); and the 5-year DM rates were
19.8% (stage IIA), 28.7% (stage IIB–C), 28.1% (stage IIIA), 34.9%
(stage IIIB), and 52.0% (stage IIIC), respectively. The Kaplan-
Meier survival probability curves by AJCC stage were plotted for
OS and DM in Figure 2. The overall log-rank tests for testing
whether the survival curves are the same among all AJCC stage
groups are significant for both OS and DM (p,0.001).
Based on our developed nomograms, the predicted probability
of 5-year overall survival and distant control for each patient was
computed, and the corresponding histograms were produced by
AJCC stage classification from stage IIA to stage IIIC, respectively
(Figure 3). The histograms showed that even within the same
AJCC stage category, there are still a substantive amount of
variability in terms of the predicted 5-year OS and DM-free
probabilities, while in average the later stage patients have a
smaller probabilities compared to earlier stage patients for both
survival outcomes. Greater variations were observed for later stage
patients (stage IIIB and IIIC) than earlier stage patients (stage IIA
to IIIC) in terms of both 5-year OS and DM-free predicted
probabilities.
Discussion
In current study, for AJCC stage II–III (7th edition) rectal
cancers without neoadjuvant treatment, we have developed
prognostic monograms with independent validation samples for
predicting OS and DM, based on demographic, clinicopatholog-
ical and adjuvant treatment information. Our models were
developed using a 20-year period institutional database; during
that time, neoadjuvant RT or CRT was not well applied in China.
Our predictive models are helpful to support decision-making in
clinical practice and follow-up protocols, especially in patients with
rectal cancer who are preoperatively under-staged and undergo
surgical resection first.
The purpose of treatment in rectal cancer is to potentially
improve symptoms through local control, increase chance of cure,
or prolong survival. Although the German Rectal Cancer Study
Group established the significant improvements in local control
and toxicity for patients with locally advanced rectal cancer
treated with preoperative CRT [4], long-term follow-up and other
clinical trials didn’t show benefit in overall survival and distant
control for patients undergoing preoperative CRT[18–21]. A
variety of factors ultimately influence a patient’s decision to receive
preoperative CRT, such as proximal tumor location, suboptimal
preoperative staging methods, inaccessible facilities for optimal
radiotherapy, patient preference, and/or financial considerations.
The potential benefits of receiving preoperative CRT must be
carefully evaluated with the potential risks. Currently, there is no
nationwide or international report about the accurate proportion
of preoperative CRT in locally advanced rectal cancer. The US
National Cancer Database (NCDB) reported that in 2008, 41% of
patients with stage I–II rectal cancer received proctocolectomy
with chemotherapy or radiotherapy, in which 80% of chemother-
apy, which is mainly accompanied by radiotherapy, was delivered
preoperatively. However, the percentage of preoperative CRT in
stage II–III rectal cancer was not reported [2]. In Canada, only an
average of 45% of stage II–III rectal cancers treated in 2007–2008
Figure 1. Nomograms developed for predicted 5-year overall survival (A) and distant control survival (B). Each variable value is
assigned a score, and the sum of scores is converted to a probability of observed events in the lowest scale.
doi:10.1371/journal.pone.0106344.g001
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Table 2. Multivariate analyses of 5-year outcomes: the final predictors for developing the nomograms.
Variable Cox PH Regression Nomogram
HR 95% CI p-value C-index 95% CI
Distant Metastases
Gender
Male vs Female 1.42 [1.07,1.88] 0.014
Age (years)
50–69 vs ,= 49 0.94 [0.69,1.27] 0.672
.= 70 vs ,=49 1.33 [0.92,1.93] 0.134
Tumor location
Mid ([5 cm, 10 cm]) vs Low (,5 cm) 0.79 [0.58,1.07] 0.122
High (.10 cm) vs Low (,5 cm) 0.78 [0.46,1.31] 0.344
Adjuvant chemotherapy
Yes vs No 0.55 [0.41,0.74] ,0.0001
Adjuvant chemoradiotherapy
Yes vs No 0.67 [0.50,0,90] 0.008 Training Data: 0.68 [0.64,0.72]
pT classification Validation Data:0.73 [0.63,0.83]
T3 vs T1–T2 1.07 [0.66,1.72] 0.781 Ten-fold Cross
‘T4’ vs ‘T1–T2’ 1.59 [1.03,2.47] 0.038 Validation
pN classification (Training Data): 0.65
‘N1a’ vs ‘N0’ 1.66 [1.05,2.62] 0.031
‘N1b’ vs ‘N0’ 2.00 [1.23,3.27] 0.005
‘N2a’ vs ‘N0’ 2.14 [1.21,3.80] 0.009
‘N2b’ vs ‘N0’ 2.56 [1.23,5.32] 0.012
CEA
.5 vs ,=5 1.26 [0.96,1.64] 0.093
LNR
Continuous* 1.11 [1.02,1.20] 0.013
Overall Survival
Gender
Male vs Female 1.37 [1.06, 1.78] 0.017
Age (years)
50–69 vs ,= 49 1.03 [0.77,1.36] 0.854
.= 70 vs ,=49 1.42 [1.00,2.02] 0.049
Tumor location
Mid ([5 cm, 10 cm]) vs Low (,5cm) 0.68 [0.52, 0.90] 0.007
High (.10 cm) vs Low (,5 cm) 0.61 [0.37, 1.01] 0.053
Adjuvant chemotherapy
Yes vs No 0.56 [0.42, 0.73] ,0.0001
Adjuvant chemoradiotherapy
Yes vs No 0.75 [0.57, 0.98] 0.033 Training data: 0.70 [0.66, 0.73]
pT stage Validation data: 0.76 [0.67, 0.86]
‘T3’ vs ‘T1–T2’ 1.20 [0.77, 1.87] 0.414 Ten-fold Cross
‘T4’ vs ‘T1–T2’ 1.68 [1.11,2.52] 0.013 Validation
pN stage (Training Data): 0.67
‘N1a’ vs ‘N0’ 1.67 [1.08, 2.59] 0.021
‘N1b’ vs ‘N0’ 2.42 [1.54, 3.79] 0.00012
‘N2a’ vs ‘N0’ 2.28 [1.33, 3.91] 0.0028
‘N2b’ vs ‘N0’ 2.75 [1.40, 5.44] 0.0035
CEA
.5 vs ,=5 1.24 [0.96, 1.59] 0.097
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were reported to undergo preoperative RT or CRT in a Canadian
nationwide cancer performance report [1,22]. In Asian countries,
much lower percentage of stage II–III rectal cancers undergo
preoperative RT or CRT, as most surgeons in Asia do not usually
recommend preoperative CRT for clinical T2 or T3 rectal cancers
[3]. The wide variation in indications and clinical applications of
neoadjuvant RT or CRT reflect the complexity of the disease,
which should alert international rectal cancer expert organizations
as well as health-care administrators. Therefore, in current clinical
circumstance, there are still a great number of patients with locally
advanced rectal cancer receiving curative surgical treatment prior
to RT or CRT. Our study will help rectal cancer patients and
physicians to pursue more individualized postoperative treatment
according to their risks of disease control and survival expecta-
tions.
With the wide utilization of neoadjuvant CRT in clinical
practice and randomized clinical trials, several studies focused on
the outcome prediction in patients with combined modality
treatment. Recently, a prediction nomogram was developed to
predict local recurrence, distant metastases, and survival for
patients with locally advanced rectal cancer treated with long-
course chemoradiotherapy (CRT) followed by surgery in five
European phase III clinical trials [16]. Postoperative ypT stage
and ypN stage were most relevant to overall survival. However, as
downstaged by preoperative CRT, the two most important
prognostic factors (ypT and ypN classfications) could not be well
applied to patients treated with curative surgery prior to adjuvant
treatment. Otherwise, the decision of neoadjuvant CRT mainly
relies on preoperative staging of the primary tumor. The accuracy
of T and N stage by preoperative MRI or endorectal ultrasound
varies, especially in N stage. A number of patients with locally
advanced rectal cancer will be under-staged preoperatively and
undergo surgery first. The postoperative treatment and outcome
prediction for this group of patients are currently lacking.
Moreover, although perioperative CRT or CT has been proved
to be effective in rectal cancer, in real clinical circumstance, there
are still a part of patients with locally advanced rectal cancer
undergoing surgery alone. According to a large-scale population-
based study through the California Cancer Registry, there were
still 33% and 18.6% of patients with stage II and stage III rectal
cancer undergoing surgery alone from the year 1994 to 2008 [23].
Similarly, 57.4% and 13.0% of patients with stage II and stage III
rectal cancer underwent surgery alone in our study. Currently, we
are lacking of studies in defining characteristics of patients who
Table 2. Cont.
Variable Cox PH Regression Nomogram
HR 95% CI p-value C-index 95% CI
LNR
Continuous* 1.12 [1.03, 1.20] 0.0046
Note: The concordance index (c-index) for the training and external validation are given for the nomogram as a performance measure; Tumor location was determined
the distance from anal verge by preoperative colonoscopy or digital examination.
*LNR was analyzed as a continuous variable.
Abbreviations: HR, hazard ratio; PH, proportional hazards; c-index, concordance index; CEA, carcinoembryonic antigen; LNR, metastatic lymph nodes ratio.
doi:10.1371/journal.pone.0106344.t002
Figure 2. The overall survival (A) and distant metastases free (B) Kaplan-Meier probability curves within each stage (AJCC 7th
Edition) classification in locally advanced rectal cancer.
doi:10.1371/journal.pone.0106344.g002
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have good outcomes without neoadjuvant therapy, particularly
with surgery alone. Our nomogram provides a helpful tool for
identifying patients with good outcomes if they were preopera-
tively under-staged and underwent surgery first. Meanwhile, as
preoperative CRT contributed small improvements in overall
survival and distant metastases, our study provided helpful tools
and comparable dataset for predicting patients’ distant control and
overall survival in locally advanced rectal cancer with multiple
treatment modalities.
The goal of our study is to develop monograms to predict
overall survival and distant metastases for patients without
preoperative treatment. To our knowledge, using the 7th edition
of AJCC staging system was the first predicting model for OS and
distant control in rectal cancer (Figure 2), especially in Asian
patients who were less represented in the AJCC stage system.
Similar survival differences among different AJCC stage categories
were observed in our patient cohort, as compared with Surveil-
lance, Epidemiology, and End Results (SEER) population-based
data [24]. Postoperative T stage and N stage were still most
significant factors to predict OS and DM rates. However, from the
predicted outcomes based on our nomograms, heterogeneities in
the risk of death and distant metastases still largely existed within
each sub-category stage from stage IIA to stage IIIC. Specifically,
from the histograms in Figure 3, the variability of predicted OS
and DM rates was observed greater in patients in stage IIIB and
IIIC than patients in stage IIA–IIIA. This suggests that the
prediction value of OS and DM may be better in patients with
stage IIIB and IIIC rectal cancer when adding these demographic
and clinicopathological variables which were not included in
TNM staging system; while for patients with stage IIA to IIIA,
molecular markers (eg. microsatellite instability, loss of heterozy-
gosity, etc.), rather than adding more clinicopathological variables,
may be benefit to further improve the accuracy of outcome
prediction. By integrating important demographic and clinico-
pathological features, our nomogram helped further individualize
the outcome prediction based on current TNM staging system.
More personalized postoperative treatment may be utilized for
preoperatively under-staged patients with rectal cancer in the same
AJCC stage.
In addition to the TN stage, metastatic lymph nodes ratio
(LNR) was reported to be a reliable prognostic factor both in colon
and rectal cancer[25–28]. However, utilization LNR in clinical
practice is relatively difficult, as optimal cut-off of the continuous
LNR value has not been established. We also found LNR was one
of most important prognostic factors for predicting DM and OS,
in addition to patients’ N stage. LNR was treated as a continuous
variable in our predicting nomograms, which contributed to
improve the performance of our model in predicting patients’
survival outcomes. Data from the five European trials found small
but statistical significant improvement in distant control for
patients with neoadjuvant CRT [16]. A recent meta-analysis of
21 randomized controlled trials from 1975 to 2011 concluded that
adjuvant 5-Fu-based chemotherapy was beneficial for rectal
cancer patients in improving overall survival and disease-free
survival [29]. However, the benefit of adjuvant chemotherapy
after combined treatment of rectal cancer is still not well defined in
single randomized trials [4,19,21]. In our patient cohort, we only
found improvements in local control in patients with any adjuvant
treatment, compared with no adjuvant treatment. Further clinical
trials are needed to explore the effect of adjuvant chemotherapy
(single agent or combination) in improving distant control and
overall survival.
Currently, there are emerged debates about adding adjuvant
radiotherapy to node positive patients who receive surgical
treatment first because of under-staged disease by preoperative
imaging. Although randomized clinical trials proved the improve-
ment of local control in node positive rectal cancer [30,31], the
risks of treatment toxicities and decremented quality of life limited
its clinical use [32,33]. A predicted nomogram for local recurrence
including demographic and clincopathological variables may help
Figure 3. Histogram of nomogram-predicted 5-year overall survival rate (A) and distant control rate (B) within each subgroup of
the 7th edition of American Joint Committee on Cancer (AJCC) stage.
doi:10.1371/journal.pone.0106344.g003
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physicians to choose patients who may benefit more from adjuvant
radiotherapy. In our study, improved local control was observed in
patients with any adjuvant treatment in univariate analysis, and
the most optimal local control were observed in patients with
adjuvant chemoradiotherapy followed by chemotherapy (Table 2).
Unfortunately, our study was not able to develop a reliable
nomogram for predicting local recurrence. Treatment variations
in adjuvant setting, heterogeneous data, lacking of statistical
power, less events in the validation group may be attributed to this.
Further studies are needed to develop a reliable predictive model
for local recurrence in preoperatively under-staged patients.
As a retrospective study, there are other limitations: detailed
regimens of adjuvant chemotherapy could not be clearly provided
for each patient; techniques of radiotherapy are changing over the
20 years; detailed information of recurrence may be unclear for
part of patients, as well as loss of follow-up problems. However,
our study still provides a valuable tool to help clinicians manage
under-staged patients with rectal cancer who undergo surgery first.
Further study is needed to provide optimal postoperative
treatment for these patients.
Conclusions
The prognostic nomograms integrated demographic and
clinicopathological factors to account for tumor and patient
heterogeneity, and thereby provided a more individualized
outcome prognostication than that by the AJCC staging system
alone. Our individualized prediction nomograms could help
physicians counsel and advise patients about their personalized
treatment strategies and follow-up protocols, especially in patients
with preoperatively under-staged rectal cancer.
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